Kinetic analysis of rhodamines efflux mediated by the multidrug resistance protein (MRP1)

Chantarawan Saengkhae1, Chatchanok Loetchutinat, Arlette Garnier-Suillerot

  • 1Laboratoire de Physicochimie Biomoléculaire et Cellulaire, Université Paris Nord, Bobigny, France.

Biophysical Journal
|August 29, 2003
PubMed

Insights

This study quantifies rhodamine dye transport by multidrug resistance-associated protein 1 (MRP1), revealing glutathione-dependent kinetics. These findings provide the first quantitative data on rhodamine efflux mediated by MRP1.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Pharmacology

Background:

  • Multidrug resistance (MDR) is often mediated by efflux pumps like P-glycoprotein and MRP1.
  • Rhodamine 123 (Rh123) is used as an assay for MDR, with suggestions it's an MRP1 substrate.
  • Quantitative studies on MRP1-mediated rhodamine efflux were lacking.

Purpose of the Study:

  • To quantitatively characterize the MRP1-mediated efflux of four rhodamine dyes.
  • To determine the kinetic parameters of rhodamine transport by MRP1.
  • To compare rhodamine efflux kinetics with other MRP1 substrates.

Main Methods:

  • Utilized a continuous fluorescence assay with four rhodamine analogs (rhodamine 6G, tetramethylrosamine, tetramethylrhodamine ethyl ester, tetramethylrhodamine methyl ester).
  • Quantified drug transport by MRP1 in living GLC4/ADR cells.
  • Measured substrate concentration gradients and glutathione dependence.

Main Results:

  • Demonstrated MRP1-mediated transport of rhodamine dyes.
  • Observed glutathione-dependent transport of rhodamine by MRP1.
  • Calculated kinetic parameters (k(a)) for rhodamine analogs, finding them similar to each other but ~10-fold lower than for anthracyclines.

Conclusions:

  • Provided the first quantitative kinetic parameters for MRP1-mediated efflux of rhodamine dyes.
  • Established that rhodamine transport by MRP1 is a glutathione-dependent process.
  • Highlighted differences in kinetic efficiency between rhodamine dyes and anthracyclines for MRP1.